Chicago - Among patients receiving a novel immune-based maintenance biotherapy regimen (mBT) for metastatic melanoma, those who developed vitiligo had longer median survival.
HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Losing a Malpractice Case May Depend on Where You Live
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
The Role We Play in Addressing Racial Disparity in Dermatology
The Mainstream Patient: February 2